Targeted Therapeutics that Address Unmet Medical Needs

We have a robust pipeline of therapeutic development programs to address several clinical IBD patient subpopulations, and plan to develop a companion diagnostic for each program. 

Therapeutic Pipeline

Program
Discovery
Lead Optimization
IND-Enabling
Phase 1
Phase 2
Phase 3
Partner
PRA023 - Anti-TL1A mAb for UC and CD
PR600 - Anti-TNF Super Family Member mAb for IBD
Europe Partnered
PR300 - GPCR Modulator Small Molecule for IBD

Prometheus has an early-stage discovery collaboration with Takeda Pharmaceuticals.

ProgramProgress
PRA023 Phase 1
PR600 Lead Optimization
PR300 Lead Optimization